Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 78 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’ February 1, 2022 FOCUS4: Learning from a landmark clinical trial April 25, 2023 Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer February 10, 2022 Cancer in My Community: Caring for Children With Cancer in Paraguay June 8, 2023 Load more HOT NEWS Study in India Could Make Immunotherapy More Affordable Worldwide September 11, 2001 – Strength is Not Always Unyielding Catch up on Behind the Science 2021 – From funding stream... A career forged in team science
